Published in Nat Genet on December 01, 2013
ESR1 Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients. Clin Cancer Res (2015) 1.18
Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA. PLoS One (2015) 1.15
HSP90 empowers evolution of resistance to hormonal therapy in human breast cancer models. Proc Natl Acad Sci U S A (2014) 1.09
Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant. Nat Commun (2016) 0.99
Epigenetic reprogramming of HOXC10 in endocrine-resistant breast cancer. Sci Transl Med (2014) 0.94
Kinetics, prognostic and predictive values of ESR1 circulating mutations in metastatic breast cancer patients progressing on aromatase inhibitor. Oncotarget (2016) 0.92
Clinical significance of monitoring ESR1 mutations in circulating cell-free DNA in estrogen receptor positive breast cancer patients. Oncotarget (2016) 0.83
Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance). J Clin Oncol (2016) 0.80
Can circulating tumor cells predict resistance in metastatic breast cancer? Clin Cancer Res (2015) 0.78
Lobular breast cancer--the most common special subtype or a most special common subtype? Breast Cancer Res (2015) 0.78
A Role for Histone H2B Variants in Endocrine-Resistant Breast Cancer. Horm Cancer (2015) 0.77
Genomic modelling of the ESR1 Y537S mutation for evaluating function and new therapeutic approaches for metastatic breast cancer. Oncogene (2016) 0.76
New Strategies in Metastatic Hormone Receptor-Positive Breast Cancer: Searching for Biomarkers to Tailor Endocrine and other Targeted Therapies. Clin Cancer Res (2016) 0.75
Steroid Hormone Receptor Positive Breast Cancer Patient-Derived Xenografts. Horm Cancer (2016) 0.75
Comparison of ESR1 Mutations in Tumor Tissue and Matched Plasma Samples from Metastatic Breast Cancer Patients. Transl Oncol (2017) 0.75
Comprehensive molecular portraits of human breast tumours. Nature (2012) 47.39
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med (2011) 13.74
Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature (2012) 8.03
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet (2013) 4.03
Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet (2013) 3.96
Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep (2013) 3.85
Altered ligand binding properties and enhanced stability of a constitutively active estrogen receptor: evidence that an open pocket conformation is required for ligand interaction. Biochemistry (1997) 2.32
Phosphorylation of the human estrogen receptor. Identification of hormone-regulated sites and examination of their influence on transcriptional activity. J Biol Chem (1994) 2.30
Estrogen receptor phosphorylation. Steroids (2003) 2.17
Constitutively active human estrogen receptors containing amino acid substitutions for tyrosine 537 in the receptor protein. Mol Endocrinol (1996) 1.99
Modulation of transcriptional activation by ligand-dependent phosphorylation of the human oestrogen receptor A/B region. EMBO J (1993) 1.99
An estrogen receptor mutant with strong hormone-independent activity from a metastatic breast cancer. Cancer Res (1997) 1.82
Applying the discovery of the Philadelphia chromosome. J Clin Invest (2007) 1.46
Mechanistic aspects of estrogen receptor activation probed with constitutively active estrogen receptors: correlations with DNA and coregulator interactions and receptor conformational changes. Mol Endocrinol (1997) 1.22
Identification of charged residues in an N-terminal portion of the hormone-binding domain of the human estrogen receptor important in transcriptional activity of the receptor. Mol Endocrinol (1993) 1.02
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med (2005) 33.60
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med (2007) 20.19
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med (2003) 13.81
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol (2009) 9.39
Estrogen carcinogenesis in breast cancer. N Engl J Med (2006) 8.17
Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med (2008) 6.54
American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol (2010) 6.39
Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol (2014) 5.61
Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst (2005) 5.55
Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med (2014) 5.18
Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory. J Clin Oncol (2008) 5.10
Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol (2011) 4.81
American Society of Clinical Oncology 2006 update of the breast cancer follow-up and management guidelines in the adjuvant setting. J Clin Oncol (2006) 4.61
HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol (2006) 4.55
Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol (2008) 4.42
Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol (2008) 4.24
Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the Eastern Cooperative Oncology Group. J Clin Oncol (2009) 3.70
Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases. Clin Cancer Res (2008) 3.67
Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. J Clin Oncol (2008) 3.40
Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J Natl Cancer Inst (2002) 3.34
Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. J Clin Oncol (2011) 3.02
Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol (2012) 2.62
A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. J Natl Cancer Inst (2013) 2.56
HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial. J Clin Oncol (2010) 2.49
Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol (2013) 2.21
The biology of breast carcinoma. Cancer (2003) 2.19
Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial. J Clin Oncol (2013) 2.15
Independent validation of candidate breast cancer serum biomarkers identified by mass spectrometry. Clin Chem (2005) 2.13
Adjuvant endocrine therapy for breast cancer: how long is long enough? Oncology (Williston Park) (2013) 2.06
Anticancer activities of novel chalcone and bis-chalcone derivatives. Bioorg Med Chem (2006) 1.96
Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria. J Natl Cancer Inst (2011) 1.94
Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17. J Clin Oncol (2007) 1.93
Preclinical and clinical evaluation of sulforaphane for chemoprevention in the breast. Carcinogenesis (2007) 1.91
Exercise manages fatigue during breast cancer treatment: a randomized controlled trial. Psychooncology (2005) 1.89
Specific inhibition of DNMT1 by antisense oligonucleotides induces re-expression of estrogen receptor-alpha (ER) in ER-negative human breast cancer cell lines. Cancer Biol Ther (2003) 1.88
Neuropathy is not associated with clinical outcomes in patients receiving adjuvant taxane-containing therapy for operable breast cancer. J Clin Oncol (2012) 1.85
Increased protein stability causes DNA methyltransferase 1 dysregulation in breast cancer. J Biol Chem (2005) 1.79
Design, synthesis, and evaluation of novel boronic-chalcone derivatives as antitumor agents. J Med Chem (2003) 1.78
Sulforaphane induces cell type-specific apoptosis in human breast cancer cell lines. Mol Cancer Ther (2007) 1.68
Release of methyl CpG binding proteins and histone deacetylase 1 from the Estrogen receptor alpha (ER) promoter upon reactivation in ER-negative human breast cancer cells. Mol Endocrinol (2005) 1.67
Inhibition of histone deacetylases promotes ubiquitin-dependent proteasomal degradation of DNA methyltransferase 1 in human breast cancer cells. Mol Cancer Res (2008) 1.59
Quantitative multiplex methylation-specific PCR analysis doubles detection of tumor cells in breast ductal fluid. Clin Cancer Res (2006) 1.58
Restoration of tamoxifen sensitivity in estrogen receptor-negative breast cancer cells: tamoxifen-bound reactivated ER recruits distinctive corepressor complexes. Cancer Res (2006) 1.58
Histone deacetylase inhibitor LBH589 reactivates silenced estrogen receptor alpha (ER) gene expression without loss of DNA hypermethylation. Cancer Biol Ther (2007) 1.55
Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancer. Cancer (2012) 1.52
Myeloid toxicity in breast cancer patients receiving adjuvant chemotherapy with pegfilgrastim support. J Clin Oncol (2006) 1.48
Estrogen receptor alpha mediates breast cancer cell resistance to paclitaxel through inhibition of apoptotic cell death. Cancer Res (2007) 1.38
Epigenetics in breast cancer: what's new? Breast Cancer Res (2011) 1.36
A phase I-II study of combined blockade of the ErbB receptor network with trastuzumab and gefitinib in patients with HER2 (ErbB2)-overexpressing metastatic breast cancer. Clin Cancer Res (2008) 1.35
A novel histone deacetylase inhibitor, scriptaid, enhances expression of functional estrogen receptor alpha (ER) in ER negative human breast cancer cells in combination with 5-aza 2'-deoxycytidine. Breast Cancer Res Treat (2003) 1.32
Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196. J Clin Oncol (2004) 1.29
Clinical cancer advances 2007: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol (2007) 1.28
The HOXB7 protein renders breast cancer cells resistant to tamoxifen through activation of the EGFR pathway. Proc Natl Acad Sci U S A (2011) 1.24
A novel polyamine analog inhibits growth and induces apoptosis in human breast cancer cells. Clin Cancer Res (2003) 1.23
American Society of Clinical Oncology endorsement of the cancer care Ontario practice guideline on adjuvant ovarian ablation in the treatment of premenopausal women with early-stage invasive breast cancer. J Clin Oncol (2011) 1.23
C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the north central cancer treatment group N9831 adjuvant trastuzumab trial. J Clin Oncol (2011) 1.21
Spermine oxidase SMO(PAOh1), Not N1-acetylpolyamine oxidase PAO, is the primary source of cytotoxic H2O2 in polyamine analogue-treated human breast cancer cell lines. J Biol Chem (2005) 1.20
Trastuzumab in breast cancer. Oncology (Williston Park) (2004) 1.19
Inhibitors of histone demethylation and histone deacetylation cooperate in regulating gene expression and inhibiting growth in human breast cancer cells. Breast Cancer Res Treat (2011) 1.18
Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial. J Clin Oncol (2004) 1.16
Transcriptomic and proteomic profiling of KEAP1 disrupted and sulforaphane-treated human breast epithelial cells reveals common expression profiles. Breast Cancer Res Treat (2011) 1.15
Inhibition of estrogen signaling activates the NRF2 pathway in breast cancer. Breast Cancer Res Treat (2010) 1.14
Race and hormone receptor-positive breast cancer outcomes in a randomized chemotherapy trial. J Natl Cancer Inst (2012) 1.13
Inhibition of SIRT1 deacetylase suppresses estrogen receptor signaling. Carcinogenesis (2009) 1.11
Methyl-group dietary intake and risk of breast cancer among African-American women: a case-control study by methylation status of the estrogen receptor alpha genes. Cancer Causes Control (2003) 1.08
Effects of a novel DNA methyltransferase inhibitor zebularine on human breast cancer cells. Breast Cancer Res Treat (2009) 1.08
Protein phosphatase 2A regulates estrogen receptor alpha (ER) expression through modulation of ER mRNA stability. J Biol Chem (2005) 1.07
PI3 kinase activation and response to Trastuzumab Therapy: what's neu with herceptin resistance? Cancer Cell (2007) 1.06
Epigenetic regulation of protein phosphatase 2A (PP2A), lymphotactin (XCL1) and estrogen receptor alpha (ER) expression in human breast cancer cells. Cancer Biol Ther (2004) 1.06
Invasive lobular carcinoma cell lines are characterized by unique estrogen-mediated gene expression patterns and altered tamoxifen response. Cancer Res (2014) 1.06
Good news about oral contraceptives. N Engl J Med (2002) 1.06
Molecular mechanisms of polyamine analogs in cancer cells. Anticancer Drugs (2005) 1.05
Polyamine analogs modulate gene expression by inhibiting lysine-specific demethylase 1 (LSD1) and altering chromatin structure in human breast cancer cells. Amino Acids (2011) 1.03
A Phase II study of the polyamine analog N1,N11-diethylnorspermine (DENSpm) daily for five days every 21 days in patients with previously treated metastatic breast cancer. Clin Cancer Res (2003) 1.02
Prognostic value of biologic subtype and the 21-gene recurrence score relative to local recurrence after breast conservation treatment with radiation for early stage breast carcinoma: results from the Eastern Cooperative Oncology Group E2197 study. Breast Cancer Res Treat (2012) 0.99
Screening for therapeutic targets of vorinostat by SILAC-based proteomic analysis in human breast cancer cells. Proteomics (2010) 0.99
Multiparametric magnetic resonance imaging, spectroscopy and multinuclear (²³Na) imaging monitoring of preoperative chemotherapy for locally advanced breast cancer. Acad Radiol (2010) 0.98
A short-term biomarker modulation study of simvastatin in women at increased risk of a new breast cancer. Breast Cancer Res Treat (2011) 0.97
Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial. Breast Cancer Res Treat (2006) 0.96
Crosstalk between lysine-specific demethylase 1 (LSD1) and histone deacetylases mediates antineoplastic efficacy of HDAC inhibitors in human breast cancer cells. Carcinogenesis (2013) 0.96
Inhibition of histone deacetylase suppresses EGF signaling pathways by destabilizing EGFR mRNA in ER-negative human breast cancer cells. Breast Cancer Res Treat (2008) 0.96
What is the current status of ovarian suppression/ablation in women with premenopausal early-stage breast cancer? Curr Oncol Rep (2009) 0.96
Epigenetic reprogramming of HOXC10 in endocrine-resistant breast cancer. Sci Transl Med (2014) 0.94
Gene expression profiling of breast cancer. Adv Surg (2008) 0.94
Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer. Breast (2013) 0.94
A "bone" fide predictor of metastasis? Predicting breast cancer metastasis to bone. J Clin Oncol (2006) 0.93
The role of the polyamine catabolic enzymes SSAT and SMO in the synergistic effects of standard chemotherapeutic agents with a polyamine analogue in human breast cancer cell lines. Cancer Chemother Pharmacol (2009) 0.93
Epigenetic regulation as a new target for breast cancer therapy. Cancer Invest (2007) 0.93
Polyamine analogues down-regulate estrogen receptor alpha expression in human breast cancer cells. J Biol Chem (2006) 0.92
Multiparametric and multinuclear magnetic resonance imaging of human breast cancer: current applications. Technol Cancer Res Treat (2004) 0.92
Regulation of polyamine analogue cytotoxicity by c-Jun in human MDA-MB-435 cancer cells. Mol Cancer Res (2004) 0.92
Detection and quantification of the evolution dynamics of apoptosis using the PET voltage sensor 18F-fluorobenzyl triphenyl phosphonium. J Nucl Med (2009) 0.92
Adjuvant hormonal therapy for premenopausal women with breast cancer. Semin Oncol (2006) 0.92
The follow-up of breast cancer. Semin Oncol (2003) 0.91
Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer. Clin Cancer Res (2009) 0.90
African American women who receive primary anthracycline- and taxane-based chemotherapy for triple-negative breast cancer suffer worse outcomes compared with white women. J Clin Oncol (2009) 0.90